TXMD is the ticker symbol for TherapeuticsMD, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks TXMD with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is TXMD a good stock to buy?

13F Pro's AI ranking engine scores TXMD at 58.8/100, ranked #971 of 2,962 stocks based on 32 fundamental signals including profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for TXMD is available at https://13fpro.ai/company/TXMD. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source TXMD data?

All TherapeuticsMD, Inc. fundamentals and ownership data come directly from SEC EDGAR. TherapeuticsMD, Inc. files with the SEC under CIK 25743. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

TherapeuticsMD, Inc.(TXMD)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

TherapeuticsMD, Inc. (TXMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TXMD at 58.8/100 on a 32-signal composite quality model, placing it at rank #971 of 2,962 stocks — the top half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), TherapeuticsMD, Inc. reports quarterly revenue of $869.0K, net income of $155.0K, an operating margin of -93.9%. Top institutional holders of TXMD by reported 13-F value include Rubric Capital Management, Clearline Capital, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. TXMD trades on the Nasdaq exchange and files with the SEC under CIK 25743. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TXMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TherapeuticsMD, Inc. directly from SEC EDGAR.

AI Quality Score

58.8/100

AI Rank

#971

Revenue

$869.0K

Net Income

$155.0K

Operating Margin

-93.9%

TXMD key financials by period

TherapeuticsMD, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	10-K/A	$3.0M	$-569.0K	-145.3%
FY 2024	10-K/A	$1.8M	$-2.2M	—
FY 2023	10-K	$1.3M	$-10.3M	—
FY 2022	10-K	$70.0M	$112.0M	1.7%
FY 2021	10-K	$2.6M	$-172.4M	—
FY 2020	10-K	$64.9M	$-183.5M	—

Institutions holding TXMD

Institutional investors reporting a position in TherapeuticsMD, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
Rubric Capital Management	1,192,191	$2.6M	2026-06-30
Clearline Capital	635,222	$1.4M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	353,697	$781.7K	2026-06-30
Tejara Capital Ltd	344,482	$761.3K	2026-06-30
ADAR1 Capital Management	342,447	$756.8K	2026-06-30
RENAISSANCE TECHNOLOGIES	146,599	$324.0K	2026-06-30
MORGAN STANLEY	129,217	$285.6K	2026-06-30
BlackRock	115,145	$254.5K	2026-06-30
GEODE CAPITAL MANAGEMENT	105,849	$234.0K	2026-06-30
CITADEL ADVISORS	86,095	$190.3K	2026-06-30

SEC EDGAR: CIK 25743 →

TherapeuticsMD, Inc.

TXMD

NasdaqSmall CapHealthcare

13F Pro Quality Score

58.8/100

Rank #971 of 2,962 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Price Chart

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

What's Driving TXMD's Business? Latest 10-Q Breakdown

AI-extracted from the 10-Q filed 2026-08-11 — Q2 FY2026 (six months ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

TherapeuticsMD recorded $1.6M in license revenue for H1 2026, up 18% YoY, but faces substantial doubt about going concern due to litigation with Mayne Pharma over $5.5M net working capital settlement and dependence on royalties from licensed products.

Biggest Revenue Drivers

License revenue – Mayne Pharma (IMVEXXY, BIJUVA, ANNOVERA, prenatal vitamins)$1.593M+18% YoY

Royalties and minimum annual royalties from exclusive U.S. license to Mayne Pharma for commercialization of licensed products at 8.0% on first $80M and 7.5% above, with $3.0M minimum annual royalty for 12 years.

License revenue – Knight and Theramex (IMVEXXY, BIJUVA international)Included in total revenue above

Knight commercializing in Canada (launched 2024); Theramex in Europe (began commercialization 2021); Israel transferred to Theramex in December 2024. Milestone revenue from Knight for IMVEXXY H1 2025 sales recognized in Q3 2026 ($365K CAD equivalent).

Biggest Revenue Drivers

Total revenue: $1.593M+18% YoY

License revenue – Mayne Pharma (IMVEXXY, BIJUVA, ANNOVERA, prenatal vitamins)$1.593M+18% YoY

License revenue – Knight and Theramex (IMVEXXY, BIJUVA international)Included in total revenue above

Largest Expense Items

General and administrative$2.930M-3.7% YoY

Decrease primarily due to lower professional fees and stock-based compensation costs.

Depreciation and amortization$0.189M-1% YoY

Entirely comprised of amortization of license rights and intangible assets (hormone therapy drug patents).

Margins: The company incurred a loss from operations of $1.539M for H1 2026 (vs. $1.976M in H1 2025), improved by 22% due to higher license revenues and lower write-offs and professional fees. However, other income (interest, sublease, miscellaneous) of $1.806M partially offset operating losses, resulting in net income of $250K.

Watch Items from the Filing

Substantial going-concern doubt: management states 'substantial doubt about ability to continue as a going concern for next twelve months' due to dependence on Mayne Pharma royalties, pending litigation, net working capital disputes, and potential need for additional financing.
Mayne Pharma litigation: filed lawsuit April 2025 for breach of contract, fraudulent inducement, and unjust enrichment over net working capital allowances; Mayne filed countersuit May 2025. Court stayed case pending dispute resolution as of May 20, 2026. Cannot estimate range of loss.
Net working capital contingency: company paid $5.5M to Mayne Pharma in December 2023 for certain trued-up amounts; disputes remain unresolved for payer rebates, wholesale distributor fees, and allowance for returns, with final determination pending.
Revenue concentration: 100% of H1 2026 license revenue derived from Mayne Pharma, Knight, and Theramex; royalty receivable of $3.394M short-term and $12.626M long-term (including minimum annual royalties) concentrated with these three partners.
Patent litigation: Mayne Pharma responsible for defense of IMVEXXY patents against generic challenges from Teva (filed 2020, litigation ongoing since April 2020) and Sun Pharma (filed July 2024); IMVEXXY Patents expire 2032–2033.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →